A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
Public ClinicalTrials.gov record NCT03138512. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Study identification
- NCT ID
- NCT03138512
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 1,641 participants
Conditions and interventions
Conditions
Interventions
- ipilimumab Biological
- ipilimumab placebo Drug
- nivolumab Biological
- nivolumab placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 6, 2017
- Primary completion
- Sep 27, 2023
- Completion
- Jan 31, 2024
- Last update posted
- Dec 17, 2024
2017 – 2024
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0019 | Birmingham | Alabama | 35205 | — |
| Local Institution - 0056 | Springdale | Arkansas | 72762 | — |
| Local Institution - 0186 | Los Angeles | California | 90048 | — |
| Local Institution - 0180 | Los Angeles | California | 90095 | — |
| Local Institution - 0002 | San Francisco | California | 94115 | — |
| Local Institution - 0185 | Aurora | Colorado | 80045 | — |
| Local Institution - 0016 | Athens | Georgia | 30607 | — |
| Local Institution - 0005 | Chicago | Illinois | 60611 | — |
| Local Institution | Chicago | Illinois | 60612 | — |
| Local Institution - 0006 | St Louis | Missouri | 63110 | — |
| Local Institution - 0012 | Howell Township | New Jersey | 07731 | — |
| Local Institution - 0007 | Buffalo | New York | 14263 | — |
| Local Institution - 0181 | New York | New York | 10029 | — |
| Local Institution - 0001 | New York | New York | 10065 | — |
| Local Institution - 0008 | Columbus | Ohio | 43210 | — |
| Local Institution - 0009 | Portland | Oregon | 97213 | — |
| Local Institution - 0010 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0014 | Greenville | South Carolina | 29607 | — |
| Local Institution - 0013 | Chattanooga | Tennessee | 37404 | — |
| Local Institution - 0183 | Nashville | Tennessee | 37212 | — |
| Local Institution - 0057 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 179 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03138512, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2024 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03138512 live on ClinicalTrials.gov.